Skip to main content
. Author manuscript; available in PMC: 2024 Jan 17.
Published in final edited form as: Acc Chem Res. 2022 Dec 29;56(2):157–168. doi: 10.1021/acs.accounts.2c00735

Figure 8.

Figure 8.

Naturally occurring SARS-CoV-2 Mpro mutants that are resistant to nirmatrelvir. (A) Mapping of the 5 drug resistant hot spot residues to the X-ray crystal structure of SARS-CoV-2 Mpro with nirmatrelvir (PDB: 7SI9). (B) The enzymatic activity and drug sensitivity to nirmatrelvir for the 20 identified naturally occurring SARS-CoV-2 Mpro mutants. (C) Plaque assay for the recombinant SARS-CoV-2 WT, nsp5S144A, and nsp5H172Y. (D) Growth curves for the recombinant SARS-CoV-2 WT, nsp5S144A, and nsp5H172Y.